Poisons Standard March 2018

Overview

The Therapeutic Goods Act 1989 (TG Act) was enacted to establish and maintain a system of controls ensuring the quality, safety, efficacy, and timely availability of therapeutic goods used or exported from Australia. This Act provides the foundation for a unified approach by state and territory governments to regulate the availability, accessibility, and safe handling of medicines and poisons. Administered by the Therapeutic Goods Administration (TGA) within the Department of Health, the Act aims to protect public health and safety by controlling the supply of therapeutic goods, particularly those containing scheduled substances. Part 6-3 of the TG Act facilitates a uniform system of access controls for goods containing scheduled substances, with the scheduling intended to mitigate risks of poisoning and misuse. The Act also mandates expert advisory committees to advise the Secretary on scheduling decisions, ensuring these are made with comprehensive consideration of health risks and public safety. The Poisons Standard, a crucial component of the TG Act, is a legislative instrument that classifies substances into various schedules, indicating the level of control over their availability. The Poisons Standard March 2018, replacing the previous February 2018 version, includes several new substances and was developed following advice from the Advisory Committee on Chemicals Scheduling (ACCS) and subsequent public consultation. This update ensures the Poisons Standard remains current with emerging health and safety considerations. The Poisons Standard is integral to both state and federal regulations, influencing restrictions on the supply of scheduled substances and advertising prohibitions for certain medicines.

Scope and Application

The Therapeutic Goods Act 1989 (TG Act) governs the quality, safety, efficacy, and timely availability of therapeutic goods used in or exported from Australia, with the Therapeutic Goods Administration (TGA), part of the Department of Health, administering these controls. The Act also provides a framework for state and territory governments to ensure the safe handling and accessibility of medicines and poisons across Australia. Part 6-3 of the Act establishes a uniform system of access controls for goods containing scheduled substances, aiming to minimise risks of poisoning and misuse. The Act prohibits advertising of certain scheduled substances to consumers, reflecting the importance of controlling their availability. The Poisons Standard, which includes schedules of substances and the degree of control over their public availability, is referred to in state and territory legislation and is updated by the Secretary of the Department of Health, with advice from the Advisory Committee on Medicines Scheduling and the Advisory Committee on Chemicals Scheduling. The Poisons Standard March 2018 replaces the previous February 2018 version, incorporating new substances into the scheduling system based on expert advice and public consultation. This instrument, being a legislative one under the Legislation Act 2003, is not subject to disallowance or scrutiny under the Human Rights (Parliamentary Scrutiny) Act 2011, and it commences on 1 March 2018.

Key Provisions

The main operative sections of the Poisons Standard March 2018, under the Therapeutic Goods Act 1989, establish a revised framework for the classification and scheduling of substances that are considered poisons. Section 52D(2) of the Act empowers the Secretary of the Department of Health to amend the existing Poisons Standard or to create a new document that replaces it, ensuring that the schedules reflect the latest expert advice and risk assessments. This new Poisons Standard March 2018, which became effective on 1 March 2018, includes specific substances such as 3-nitro-p-hydroxyethylaminophenol and o-toluidine, which were incorporated into the schedules for the first time. These schedules categorise substances according to the level of control needed to safeguard public health and safety, ranging from substances that require minimal restrictions to those that necessitate stringent controls. The obligations imposed by the Poisons Standard March 2018 on the parties and entities it governs are primarily centred around adherence to the schedules and the restrictions placed on the supply and use of scheduled substances. This includes manufacturers, suppliers, and retailers who must ensure that their products comply with the appropriate scheduling requirements. For example, substances classified under Schedule 4 or Schedule 8 cannot be advertised directly to consumers. Furthermore, entities must ensure that their practices align with the Poisons Standard to avoid legal repercussions and to contribute to the overall public health safety. The Therapeutic Goods Administration (TGA) plays a pivotal role in monitoring compliance and enforcing the provisions of the Poisons Standard. The Poisons Standard March 2018 also outlines various offences and penalties for breaches of its provisions. For example, the Act prohibits the advertising of prescription medicines containing substances in Schedule 4 or Schedule 8, or over-the-counter medicines with substances in Schedule 3 that are not listed in Appendix H. Violations of these advertising restrictions can result in significant penalties. Under the TG Act, offences related to the supply or advertising of scheduled substances can lead to criminal charges and substantial fines. The maximum penalties can vary depending on the severity of the breach and can include both criminal sanctions and civil penalties. The Act does not provide specific maximum penalties in the explanatory statement but indicates that breaches can lead to fines and imprisonment under the TG Act. It is crucial for entities involved in the supply and advertising of therapeutic goods to be fully aware of their obligations to avoid these severe consequences.